CRVO — CervoMed Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1053691 ·
Last close
$1.50
Market Cap
$22.68M
52W High
$10.00
52W Low
$1.27
ADV30
769,275
Next earnings
2026-11-09

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -6,104,950 -5,895,431 21,330,143 6,059,804 3,974,226
Jun 2026 0 — -6,678,551 -6,571,656 25,992,471 22,462,577 3,032,174
Mar 2026 0 — -8,110,524 -7,964,158 15,112,918 7,941,751 4,497,203
Dec 2025 0 — -8,331,519 -8,087,290 22,879,018 8,235,469 4,656,117

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-27,977,672
Investing CF
$23,192,573
Financing CF
$18,926,963
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.18
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-112,233,665
Inventory
—
Receivables
$0
ST Investments
$2,475,595
EBIT TTM
$-31,164,793
Pretax Income TTM
$-30,349,743
Interest Exp TTM
—
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$331,295
EBITDA
—
Free Cash Flow
$-16,289,585
Enterprise Value
$-3,469,055
Total Cash
$24,938,172
Total Debt
$0
Shares Out
15,119,096
Trailing EPS
$-3.21
Book Value
$1.97
ROE
-107.6%
ROA
-60.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -28,294,877 -26,966,367 22,879,018 4,656,117 18,222,901 -23,449,963
Dec 2024 0 -18,227,131 -16,290,695 43,081,610 3,879,282 39,202,328 -16,530,827
Dec 2023 0 -7,812,895 -2,171,873 9,972,521 2,595,747 7,376,774 -7,449,847
Dec 2022 0 -3,475,534 -5,803,047 4,157,706 37,442,765 -33,285,059 -2,572,759

TTM Snapshot

Revenues TTM
$331,295
NetIncome TTM
$-30,349,743
OpCashFlow TTM
—
Assets (Latest)
$25,992,471
Forward EPS
$-1.39

Peers — same industry

TickerNameMarket CapLastDaily %
BYSI BeyondSpring Inc. $23.02M $0.56 —
ETST Earth Science Tech, Inc. $23.17M $0.08 —
TXMD TherapeuticsMD, Inc. $22.11M $1.91 —
IXHL Incannex Healthcare Inc. $21.83M $1.74 —
CPHI CHINA PHARMA HOLDINGS, INC. $21.51M $0.50 —

News headlines (Yahoo Finance, 1h cache)

CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
2026-11-16 21:02 · Yahoo
CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
2026-11-09 12:30 · Yahoo
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
2026-10-29 11:30 · Yahoo
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Brea
2026-10-12 11:30 · Yahoo
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
2026-09-22 11:30 · Yahoo
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT
2026-09-10 11:30 · Yahoo
CervoMed to Participate in September Investor Conferences
2026-09-08 11:30 · Yahoo
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
2026-07-14 11:30 · Yahoo
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
2026-07-09 11:30 · Yahoo
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
2026-07-06 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.